Drugs / Boostrix-IPV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT03606096 | Jan 2019 → May 2022 | pertussis | London School of Hygiene and Tropical Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01294605 | Apr 2003 → Sep 2004 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT03697798 Comparator | Apr 2018 → Jan 2020 | pertussis | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT02145624 Comparator | Oct 2014 → Jun 2017 | — | Public Health England | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Boostrix IPV | “(Boostrix® IPV, GlaxoSmithKline (GSK)) combination vaccine” NCT03697798 ↗ |
| Known as | BoostrixTM | “GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)” NCT01294605 ↗ |
| Modality | Vaccine | “Boostrix IPV (contains antigens against pertussis, tetanus, diphteria and polio)- a vaccine recommended for pregnant women” NCT03606096 ↗ |
| Route | Intramuscular | “Intramuscular, single dose” NCT01294605 ↗ |